Kuros Biosciences will present results from clinical case studies of MagnetOs Granules at the 15th annual State of Spine Surgery Think Tank on June 21 to June 23 in Aruba.
Here are three things to know:
1. Dr. Alwyn Jones, a consultant orthopedic spinal surgeon at Spire Cardiff Hospital in the United Kingdom, implanted MagnetOs in the spines of five patients requiring spinal fusion in 2017.
2. Major takeaways from the case studies include:
- MagnetOs Granules were well-tolerated and no device-related adverse events were reported
- MagnetOs Granules were easy to apply as a standalone graft, when mixed with bone marrow aspirate or local bone
- Resorption and remodeling of MagnetOs Granules was evident from as early as three months after implantation
- The granules promoted spinal fusion in a mixed patient cohort when implanted using five different surgical approaches
3. MagnetOs is a bone graft substitute comprised of biphasic calcium phosphate with a submicron surface topography intended to direct bone formation after implantation.
More articles on biologics:
Wright Medical wins premarket approval for biologic alternative — 6 insights
New study will compare Kuros Biosciences' MagnetOs, autograft for spinal fusion: 3 insights